Fig. 5.

Changes in dendritic cell and immature myeloid cell population in anti-VEGF-treated patients. Peripheral blood was drawn from patients, who were enrolled in anti-VEGF clinical trials, before and 2 weeks after anti-VEGF antibody administration. The percentages of DC (Lin⁻ HLA-DR⁺, a) and immature myeloid cells (Lin⁻ HLA-DR⁻, b) were shown for individual patients. Anti-VEGF antibody administration induced significant decrease in the number of immature myeloid cells (P = 0.012) and mild increase of DC